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Sex Med 2Introduction: An increased risk of sexual health problems is seen among patients with chronic illnesses. The
background is likely to be multifactorial, but it remains poorly understood.
Aim: To investigate the sexual health and functioning of patients with rheumatoid arthritis (RA) and to examine gender
differences, general population comparisons, and possible somatic, psychological, and disease-specific determinants.
Methods: A cross-sectional study using a digital questionnaire distributed among 380 patients diagnosed with
RA in a Danish university hospital outpatient setting.
Main Outcome Measure: Arangeofpatient-reportedoutcomeswereobtained, including scores fromthevalidated rating
scale Changes in Sexual Functioning Questionnaire. Furthermore, individual medical record information was collected.
Results: A total of 329 patients (250 women and 79 men) were included (age range: 25e73 years; mean age:
57.2 years). The Changes in Sexual Functioning Questionnaire scoring indicated an overall sexual dysfunction in
33.8% of men and 58.1% of women.More than one-third (37.6%) of patients felt that RA had made their sex
life more complicated, and 32.4% feared that this might someday be the case. In total, 29.2% patients had
experienced sexual problems due to their RA treatment. Of the respondents who experienced RA-related fatigue,
46.5% reported that this impacted negatively on their sexual activity. The risk of one or more sexual health
adversities was significantly correlated with female gender, older age, moderate or severe depression, moderate to
moderately high loneliness, more than 2 comorbidities, and a fatigue score above 75 out of 100 on a visual
analogue scale. Compared to the general population, significantly fewer patients with RA considered their sex life
important, and significantly fewer patients appraised their current sex life as good or very good. Moreover,
significantly more women with RA (32.1%) than women from the general population (15.7%) had not had any
sex life during the past year. A vast majority of patients with RA (93.5% of women and 85.5% of men) had not
discussed sexual issues with a health-care professional during the last 5 years. Of all, 32.5% would like health-care
professionals to address sexual topics in the consultation occasionally.
Conclusion: Sexual dysfunction is highly prevalent in patients with RA, but the problems are not regularly
addressed in consultations provided by the rheumatology department. Bay LT, Graugaard C, Nielsen DS, et al.
Sexual Health and Dysfunction in Patients With Rheumatoid Arthritis: A Cross-sectional Single-Center
Study. Sex Med 2020;8:615e630.
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616 Bay et alINTRODUCTION
It is well-established that sexuality and health are intimately
entwined—sexual functioning may impact dimensions of general
health both positively and negatively. In contrast, dimensions of
general health may either facilitate or disrupt sexual functioning.
Mental diseases constitute major risk factors for sexual difficulties
and dysfunctions as many mental health problems, for example,
depression, may impair sexual life in all domains, including
desire, arousal, and satisfaction.1 However, somatic diseases may
also pose a risk to sexual life and functioning in different do-
mains, for example, due to physical impairment, pain, and side
effects from medication.2,3
The mechanisms behind the increased risk of sexual problems
among chronically ill patients are multifactorial. They are the
result of a complex interplay between biological, psychological,
and social factors: Somatic patients usually experience both bio-
logical challenges (ie, physical complications and drug side effects
such as fatigue, pain, and nausea),2,4 psychological challenges (ie,
mood swings, lack of self-confidence, and body image disorders)5-7
and social challenges (ie, social exclusion, loneliness, and relational
tensions)8 that may in sum lead to sexual dysfunctions, relational
distress, and increased overall vulnerability.
Rheumatoid arthritis is a chronic inflammatory autoimmune
disease that causes joint swelling, pain, and fatigue resulting in
disfiguration, disability, and psychosocial limitations. Such
strains may impact sexual functioning and relational compe-
tencies negatively.9 Concurrently, patients with RA are at
increased risk of cardiovascular disease, which further adds to the
hazard of sexual dysfunctions.4,10
The first choice of RA treatment is methotrexate (MTX).
Some studies suggest that MTX may increase the risk of erectile
dysfunction and Peyronie’s disease in male patients.11 Other RA-
relevant medications may increase the risk of sexual dysfunctions
in both genders, but results are far from unequivocal.11,12
Despite chronic patients’ well-known need for sexual coun-
seling,13,14 numerous studies have shown a striking lack of priori-
tization of the subject in the health system,8,14-16 leading to an
unfortunate “two-way taboo” between patients and their health-
care professionals.17
Generally, sexual dysfunctions are more frequent among
women than men,18 and this tendency was recently confirmed by
a representative sample of 15- to 89-year-old Danes.19 In addition,
most studies on sexual dysfunctions among patients with RA focus
on female participants because most patients with RA are women
(male-female ratio, 1:4). In Denmark, gender differences in sexual
health have been studied in patients with chronic diseases such as
diabetes and cardiovascular disease.16,20 These studies have sug-
gested that women’s sexual functioning is mostly influenced by
mental factors, whereas men’s sexual functioning is mainly influ-
enced by physical factors.21 To our knowledge, studies on the
sexual impact of RA on both men and women are scarce.This article focuses on the sexuality of Danish patients with RA,
and it aims to (i) investigate the sexual health and functioning, (ii)
ascertain differences in sexual outcomes between men and women,
(iii) establish possible risk factor for sexual ill-health among pa-
tients with RA, and (iv) to compare patients with RA to the
general population concerning central sexual variables. Further-
more, the study aims (v) to highlight the request for sexual
counseling expressed by the participating patients.METHODS
Study Design
The study design was a cross-sectional questionnaire survey
with consecutive enrolment of patients with RA and subsequent
collection of relevant information from the individual medical
records. Data were collected in an outpatient university
department of rheumatology using a digital database. The
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guidelines for observational studies
were applied.22Participants
Patients diagnosed with RA (M059 seropositive RA, M060
seronegative RA, M069 RA no specification) were included.
Participants must be older than 18 years of age and able to speak
and understand Danish.
Participants were consecutively recruited among patients with
RA visiting the outpatient clinic of rheumatology at Odense
University Hospital, from December 4th, 2017, to June 1st,
2018. The digital survey was distributed via email to patients
between April 24th, 2018, and September 5th, 2018. The
collection of data ended on October 1st, 2018 (Figure 1). The
recruitment period was restricted because of the time limits of
the study.
The average age of the participants was 57.2 years (range:
25e73 years), and the mean disease duration was 13.8 years
(range: 2.3e53.3 years). Most of both men (94.8%) and women
(88.0%) identified themselves as heterosexuals.
Of the 380 patients (90 men and 290 women) invited to
participate in the study, 329 (250 women and 79 men) answered
at least the baseline items including demographic and disease-
specific questions (response rate: 86.6%) (Figure 1).Measurements
Demographics, Lifestyle, and Disease-Specific Information
Self-reported baseline data included information about de-
mographics (education level, relationship, and cohabitation sta-
tus), lifestyle factors (alcohol, smoking, and body mass index).
Disease-related information (disease duration, medication use,
pain) was collected as well as fatigue reported on a visual analog
scale (VAS) and comorbidity using Charlson’s ComorbiditySex Med 2020;8:615e630
Men (n=79) Women (n=250)
Enrolment
Ques onnaires: *
HAQ (=78)
UCLA Loneliness (77)
BDI (=77)
Ques ons about sexual life (76)
CSFQ (n=77)
Ques onnaires: *
HAQ (=248)
UCLA Loneliness (=248)
BDI (=242)
Ques ons about sexual life (=232)
CSFQ (n=229)
Assessed for eligibility (n=380)
Did not fill in ques onnaire (non -
responders) (n=45)
Missing baseline data (n=6)
PROMS
Gender
Included (n=329)
Figure 1. Flow Diagram. *Listed in the same order as when presented to respondents. Responses were mandatory to continue to next
questionnaire. BDI ¼ Beck Depression Inventory; CSFQ ¼ Changes in Sexual Functioning Questionnaire; HAQ ¼ Health Assessment
Questionnaire; UCLA ¼ University of Los Angeles.
Sexual Health & Dyfunction in Patients With RA 617Index.23 Paraclinical data (anticitrullinated peptide antibody and
immunoglobulin rheumatoid factor) were collected from indi-
vidual medical records.
Participants completed 4 validated questionnaires: the gender-
specific Changes in Sexual Functioning Questionnaire
(CSFQ-14) that examines changes in sexual function due to illness
and/or treatment in 5 domains (score range: 14e70; cutoff indi-
cating a sexual dysfunction: 41 [men] and 47 [women])24,25;
The Health Assessment Questionnaire (HAQ) (score range:
0e3)26; the University of California Los Angeles (UCLA) Loneli-
ness Scale (score range: 20e80)27; the Beck Depression Inventory
(BDI) (score range: 0e63; cutoff for severe depression: 29).28Comparative Data from External Sources
To compare specific outcomes to the general Danish population,
4 questions were duplicated verbatim from the Danish Project
SEXUS, which is a comprehensive population-based cohort study
on sexual health among 15- to 89-year-old Danes (n ¼ 62,675).
The study was carried out in 2017e2018, and a thorough report of
key findings was published online in October 2019.19 The vastSex Med 2020;8:615e630Project SEXUS sample was used as a control group. Comparisons
were performed on age groupeadjusted Project SEXUS data.Statistical Methods
All data were processed by Stata,29 and the categorical
descriptive variables were reported both gender specifically and in
total. All results were reported as counts with proportions and
numerical variables. Mean values with SD were calculated
depending on the normality of the variable as evaluated by
quantile-quantile plots. Total gender-specific scores were calcu-
lated for the CSFQ-14,30 HAQ,26 UCLA,27 BDI,28 and domain
scores of the CSFQ-14.
Univariate linear regressionanalysiswasusedtocompare theCSFQ
scale outcomes between genders, and univariate logistic regression
analysis was used to compare proportions below CSFQ cutoffs.
To investigate possible associations between sexual health
variables and various determinants, univariate logistic regression
was used (not shown), and a multivariate logistic regression
model including the covariates specified in Table 4 and stratified
by gender was developed.
Table 1. Basic sociodemographic and disease-specific data
Basic data Menk, N ¼ 79 (%) Womenk, N ¼ 250 (%) Total, N ¼ 329 (%)
Age, mean [SD] 58.0 [8.61] 57.0 [10.10] 57.2 [9.76]
25e44 5 (6.3) 31 (12.4) 36 (10.9)
45e64 50 (63.3) 162 (64.8) 212 (64.4)
65e73 24 (30.4) 57 (22.8) 81 (24.6)
Sexual orientation
Heterosexual 73 (92.4) 206 (82.4) 279 (84.8)
Homosexual 0 (0.0) 2 (0.8) 2 (0.6)
Bisexual 0 (0.0) 0 (0.0) 0 (0.0)
Asexual 0 (0.0) 2 (0.8) 2 (0.6)
Don’t know 3 (3.8) 15 (6.0) 18 (5.5)
None of the above/missing 3 (3.8) 25 (10.0) 28 (8.5)
Education†
Secondary education 19 (24.1) 49 (19.6) 68 (20.7)
Youth education or postcompulsory education 2 (2.5) 6 (2.4) 8 (2.4)
Low or intermediate further education 51 (64.6) 160 (64.0) 211 (64.1)
High further education 5 (6.3) 25 (10.0) 30 (9.1)
Never completed any education 2 (2.5) 9 (3.6) 11 (3.3)
Don’t know 0 (0.0) 1 (0.4) 1 (0.3)
Relationship status
Single 13 (16.5) 72 (28.8) 85 (25.8)
In a relationship 66 (83.5) 178 (71.2) 244 (74.2)
Cohabitation status
Living alone 15 (19.0) 64 (25.6) 79 (24.0)
Living together with partner and/or children 64 (81.0) 186 (74.4) 250 (76.0)
BMI‡ (n ¼ 326)
BMI, mean [SD] 27.28 [3.8] 26.92 [6.2] 27.01 [5.7]
<18.5 0 (0.0) 9 (3.6) 9 (2.8)
18.5e24.9 23 (29.1) 95 (38.5) 118 (36.2)
25e29.9 41 (51.9) 77 (31.2) 118 (36.2)
30e39.9 15 (19.0) 58 (23.5) 73 (22.4)
40 0 (0.0) 8 (3.2) 8 (2.5)
Smoking
No daily smoking 62 (78.5) 205 (82.0) 267 (81.2)
Daily smoking 17 (21.5) 45 (18.0) 62 (18.8)
Alcohol consumption (recent week)
0 units 33 (41.8) 158 (63.2) 191 (58.1)
1e7 (females)/1e14 (males) 37 (46.8) 68 (27.2) 105 (31.9)
7þ (females)/14þ (males) 9 (11.4) 18 (7.2) 27 (8.2)
Missing 0 (0.0) 6 (2.4) 6 (1.8)
Comorbidity (Charlson’s Comorbidity Index)
(self-reported) (n ¼ 329)
0e1 74 (93.7) 237 (94.8) 311 (94.5)
2þ 5 (6.3) 13 (5.2) 18 (5.5)
Anti-CCP/ACPA (n ¼ 329)
Negative* 15 (19.0) 50 (20.0) 65 (19.8)
Positive 47 (59.5) 128 (51.2) 175 (53.2)
Missing data 17 (21.5) 72 (28.8) 89 (27.1)
IgM-RF (n ¼ 329)
Negative* 11 (13.9) 42 (16.8) 53 (16.1)
Positive 56 (70.9) 149 (59.6) 205 (62.3)
Missing data 12 (15.2) 59 (23.6) 71 (21.6)
(continued)
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Table 1. Continued
Basic data Menk, N ¼ 79 (%) Womenk, N ¼ 250 (%) Total, N ¼ 329 (%)
Biologic treatment (n ¼ 329)
Previously treated 8 (10.1) 21 (8.4) 29 (8.8)
Presently treated 22 (27.8) 74 (29.6) 96 (29.2)
Never treated/unknown/missing§ 49 (62.0) 155 (62.0) 204 (62.0)
Methotrexate (n ¼ 329)
Previously treated 18 (22.8) 65 (26.0) 83 (25.2)
Presently treated 57 (72.2) 167 (66.8) 224 (68.1)
Never treated/unknown/missing§ 4 (3.1) 18 (7.4) 22 (6.7)
Disease duration, years, mean [SD] 11.84 [7.95] 14.42 [10.19] 13.80 [9.75]
Physical function (HAQ score) (n ¼ 326)
HAQ mean [SD] 0.48 [0.58] 0.94 [0.74] 0.83 [0.73]
0e1 (mild to moderate disability) 63 (80.8) 134 (54.0) 197 (60.4)
1e2 (moderate to severe disability) 13 (16.7) 87 (35.1) 100 (30.7)
2e3 (severe to very severe disability) 2 (2.6) 27 (10.9) 29 (8.9)
RA-related pain (VAS), mean [SD] (n ¼ 326) 32.55 [21.40] 39.90 [24.17] 38.14 [23.72]
RA-related fatigue (VAS), mean [SD] (n ¼ 326) 41.49 [24.85] 50.92 [26.25] 48.66 [26.20]
Depression (BDI score) (n ¼ 319)
BDI mean [SD] 6.55 [5.36] 9.71 [8.18] 8.95 [7.71]
13 (minimal or no depression) 65 (84.4) 180 (74.4) 245 (76.8)
14e19 (light depression) 10 (13.0) 31 (12.8) 41 (12.9)
20e28 (moderate depression) 2 (2.6) 23 (9.5) 25 (7.8)
29 (severe depression) 0 (0.0) 8 (3.3) 8 (2.5)
Loneliness (UCLA Loneliness score) (n ¼ 319)
UCLA mean [SD] 34.34 [12.12] 36.44 [12.86] 35.94 [12.70]
20e34 (low) 37 (48.1) 110 (45.5) 147 (46.1)
35e49 (moderate) 32 (41.6) 90 (37.2) 122 (38.2)
50e64 (moderately high) 8 (10.4) 39 (16.1) 47 (14.7)
65e80 (high) 0 (0.0) 3 (1.2) 3 (0.9)
Abbreviations: ACPA ¼ anti-citrullinated protein antibodies; BDI ¼ Beck Depression Inventory; BMI ¼ body mass index; CCP ¼ cyclic citrullinated peptide;
HAQ ¼ Health Assessment Questionnaire; IgM-RF ¼ immunoglobulin M rheumatoid factor; RA ¼ rheumatoid arthritis; UCLA ¼ University of California Los
Angeles; VAS ¼ Visual Analog Scale.
*Negative Anti-CCP and negative IgM-RF ¼ as defined by local laboratory cutoffs.
†Level of education: Secondary education (7e10 years education), youth education or postcompulsory education (10e12 years education), low further
education/intermediate further education (13e15 years education), high further education (15e17 years of education), never completed any education
(0e6 years education).
‡BMI < 18.5 underweight; 18.5e24.9 normal weight; 25e29.9 overweight; >30e39.9 severe overweight; BMI > 40 extreme overweight.
§Categories never treated/unknown/missing merged due to small numbers
kIdentification as transgender or nonbinary gender was not addressed in the questionnaire.
Sexual Health & Dyfunction in Patients With RA 619Key data from the patients with RA were compared to gender-
stratified population data from Project SEXUS, using the chi-
square test or Fisher’s exact test in case of counts below 5. The
data from Project SEXUS were weighted with regard to general
population demographics, and for comparative purposes, only
25- to 73-year-old respondents were included.
P < .05 was considered statistically significant.
Missing values were excluded from each specific analysis but
reported as separate categories.Sex Med 2020;8:615e630Ethical Considerations
All procedures were conducted in accordance with the ethical
standards of the Danish Code of Conduct for Research Integrity.
In concordance with the Danish Law of Research for survey
studies, the study was not registered at the Danish National
Committee on Health Research Ethics. The study was registered
by the Danish Data Protection Agency (case number: 2008-58-
003). Furthermore, the study was reported to the Danish Patient
Safety Authority to obtain permission to collect data from
medical records (case number: 3-3013-1445/1/).
Table 2. Domains of sexual dysfunction according to the Sexual Functioning Questionnaire
All respondents (n ¼ 306) Men (n ¼ 77) Women (n ¼ 229) P value, c2 test
Changes in Sexual Functioning Questionnaire, mean [SD] 48.58 [10.26] 36.95 [10.87] <.001
Sexual dysfunction,* n (%) 26 (33.8) 133 (58.1)
Pleasure, mean [SD] 3.26 [1.16] 2.61 [1.30] .003
Pleasure dysfunction,† n (%) 42 (54.5) 167 (72.9)
Desire/frequency, mean (SD) 6.09 [1.96] 4.48 [1.71] .003
Desire/frequency dysfunction,† n (%) 61 (79.2) 139 (60.7)
Desire/interest, mean (SD) 8.12 [2.90] 5.48 [2.25] .019
Desire/interest dysfunction,† n (%) 60 (77.9) 203 (88.6)
Arousal/excitement, mean (SD) 10.88 [3.27] 7.22 [3.04] <.001
Arousal/excitement dysfunction,† n (%) 49 (63.6) 212 (92.6)
Orgasm/completion, mean (SD) 10.74 [2.91] 8.17 [3.86] .167
Orgasm/completion dysfunction,† n (%) 57 (74.0) 150 (65.5)
Significant P values in italic.
*Risk of sexual dysfunction cutoff: men < 47, women < 41.
†Cutoff subdomains: pleasure ¼ men < 4, women < 4; desire/frequency ¼ men < 8, women < 6; desire/interest ¼ men < 11, women < 9; arousal/
excitement ¼ men < 13, women < 12; orgasm/completion ¼ men < 13, women < 11.
620 Bay et alAll participants signed a consent form after reviewing both oral
and written information.RESULTS
Basic Gender Differences
As shown in Table 1, marked differences between male and
female patients were seen in several basic categories: More
women than men were single (28.8% vs 16.5%), more women
than men were within a normal weight range (38.5% vs 29.1%),
more women than men showed signs of moderate/severe
depression (12.8% vs 2.6%), and men tended to consume more
alcohol than women. The mean HAQ score was 0.83, and a
higher proportion of men (80.8%) than women (54.0%) scored
in the lowest group (0e1 points), indicating a high level of
physical functioning.Sexual Dysfunction
In total, 306 (77 men and 229 women) of 329 respondents
answered the CSFQ questionnaire and the basic questions con-
cerning their sexual life. Overall, 33.8% and 58.1% of men and
women, respectively, had a CSFQ score indicative of sexual
dysfunction. Women reported significantly more sexual dys-
functions than men in the domains of pleasure (72.9% vs
54.5%, P < .001), desire/interest (88.6% vs 77.9%, P ¼ .003),
and arousal/excitement (92.6% vs 63.6%, P < .001), while men
exhibited more, yet nonsignificant, signs of orgasm/completion
dysfunction (74.0% vs 65.5%, P ¼ .167) and significantly more
signs of desire/frequency dysfunction (79.2% vs 60.7%,
P ¼ .019) than women (Table 2). Nearly one-fifth (18.4%) of
male respondents had used medication to treat erectile
dysfunction (Table 3).
The multivariate analysis (Table 4) revealed that women had a
significantly higher risk of sexual dysfunction within the lastmonth (measured by the CSFQ) than men (odds ratio [OR],
2.5). The risk of sexual dysfunction was significantly higher in
the age groups 45e65 years (OR, 3.5) and þ65 years (OR, 10.6)
than in the age group <45 years. The presence of fatigue above
75 on a 100-point VAS also increased the risk of sexual
dysfunction substantially (OR, 4.1).Sexual Life Related to RA
As depicted in Table 3, a total of 37.6% of respondents re-
ported that RA had made their sexual life more complicated to
some or a high extent, and 32.4% feared that RA would
complicate their sex life in the future. Almost half (46.5%) of
respondents, who experienced RA-induced fatigue, found that
the fatigue had impacted negatively on their sexual activity, and
almost one-third (29.2%) reported that they had experienced
sexual problems caused by their medical RA treatment. Of all,
29.9% (32.2% of women vs 22.4% of men) claimed that RA
had altered their body image negatively.
A vast majority (91.6%; 85.5% of men vs 93.5% of women)
stated that they had not discussed sexual issues with a health-care
professional within the past 5 years. Approximately, one in 10
(10.7%; 6.9% of women vs 22.4% of men) reported that a
health professional had addressed their sexual life about RA at
least once during the recent year. One-third (32.5%; 27.2% of
women vs 48.7% of men) reported that they would like health
professionals to address sexual issues.
Reporting a bad/very bad sex life during the last year was
significantly associated with having light or severe depressive
symptoms (OR, 4.4; OR, 31.9), and the same was true for having
a UCLA Loneliness Scale score between 50 and 64 (OR, 6.0). A
significantly increased risk of lacking sexual meaningfulness and
pleasure during the past year was seen in þ65-year-olds compared
to younger age groups (OR, 5.7), in respondents with UCLA
Loneliness Scale scores between 35 and 49 (OR, 3.7) and betweenSex Med 2020;8:615e630
Table 3. Basic questions concerning sexuality
Questions about sexuality Men, n (%) Women, n (%) Total, n (%)
To what extent did you experience that rheumatoid arthritis (RA)
made your sex life more complicated?
To a high/some extent 25 (32.9) 91 (39.2) 116 (37.6)
To a low extent/not at all 48 (63.1) 115 (49.6) 163 (52.9)
Don’t know 3 (3.9) 26 (11.2) 29 (9.4)
To what extent do you fear that RA will complicate your sex life in
the long run?
To a high/some extent 31 (40.8) 69 (29.7) 100 (32.4)
To a low extent/not at all 36 (47.4) 114 (49.1) 150 (48.7)
Don’t know 9 (11.8) 49 (21.1) 58 (18.8)
Did your experience of fatigue influence your sexual activity?*
No 33 (47.8) 94 (43.3) 127 (44.4)
Yes 31 (44.9) 102 (47.0) 133 (46.5)
Missing 5 (7.2) 21 (9.7) 26 (9.1)
Have you ever experienced sexual problems caused by the
medical treatment for RA?
No 41 (53.9) 101 (43.5) 142 (46.1)
Yes 23 (30.3) 67 (28.9) 90 (29.2)
Don’t know 12 (15.8) 64 (27.6) 76 (24.7)
Have you ever used medication for treatment of erectile
dysfunction (ED)?
No 62 (81.6) N/A 62 (81.6)
Yes 14 (18.4) N/A 14 (18.4)
To what extent did RA alter your body image?
My body image is unchanged 47 (61.8) 113 (48.7) 160 (51.9)
My body image has become more positive 3 (3.9) 10 (4.3) 13 (4.2)
My body image has become more negative 17 (22.4) 75 (32.3) 92 (29.9)
Don’t know 9 (11.8) 34 (14.7) 43 (14.0)
To what extent do you think that RA altered your partner’s view
on your body?†
His/her view is unchanged 44 (69.8) 113 (66.9) 157 (67.7)
His/her view has become more positive 1 (1.6) 3 (1.8) 4 (1.7)
His/her view has become more negative 5 (7.9) 8 (4.7) 13 (5.6)
Don’t know 13 (20.6) 45 (26.6) 58 (25.0)
During the last 5 years, did you discuss sexual questions or
problems with a health-care professional?
No 65 (85.5) 217 (93.5) 282 (91.6)
Yes, and I initiated the discussion 7 (9.2) 7 (3.0) 14 (4.5)
Yes, and the healthcare professional initiated the discussion 1 (1.3) 3 (1.3) 4 (1.3)
Don’t know 3 (3.9) 5 (2.2) 8 (2.6)
During the last year, how often did a health-care professional
address your sexual life in relation to RA?
At least one time (several/a couple of/one time(s)) 17 (22.4) 16 (6.9) 33 (10.7)
Not at all 55 (72.4) 199 (85.8) 254 (82.5)
Don’t know 4 (5.3) 17 (7.3) 21 (6.8)
To what extent do you want health-care professionals to
occasionally address your sexual life and offer you
information, guidance, and other assistance?
To a high/some/low extent 37 (48.7) 63 (27.2) 100 (32.5)
Not at all 30 (39.5) 127 (54.7) 157 (51.0)
Don’t know 9 (11.8) 42 (18.1) 51 (16.6)
*Only participants who responded positively on experiencing RA-induced fatigue.
†Only participants who responded positively to having a partner.
Sex Med 2020;8:615e630
Sexual Health & Dyfunction in Patients With RA 621
622 Bay et al50 and 64 (OR, 6.1) and in respondents who reported fatigue
between 35 and 74 (OR, 4.7) on a 100-point VAS.
Having more than 2 comorbidities on the Charlson’s Co-
morbidity Index (OR, 4.4) or displaying signs of a light
depression (OR, 2.8) increased the risk of reporting that sexual
needs had not/to a low extent been met in the past year.
Having a partner increased the risk of experiencing sexual
problems due to RA treatment (OR, 7.4) and so did a score
between 35 and 49 on the UCLA Loneliness Scale (OR, 2.9).
Reporting RA-induced sex life complications to a high or some
extent was significantly associated with 2 or more comorbidities
(OR, 4.0), low alcohol intake (OR, 2.1), and current treatment
with MTX (OR, 3.3).
Having a partner (OR, 4.3) and high alcohol consumption
(OR, 3.4) also increased the risk of having a negative body image,
as did signs of moderate or severe depression (OR, 4.5; OR, 38.3).Sexual Health in Patients With RA Compared to the
General Population
When comparing our findings among patients with RA to
nationally representative and age groupematched data from the
general Danish population (Table 5), significantly fewer male
patients than male controls (79.2% vs 90.3%, P ¼ .012) and
female patients than female controls (54.0% vs 75.4%,
P < .001) considered it important to have a good sex life.
Similarly, significantly fewer male patients than male controls
(39.0% vs 49.9%, P ¼ .043) and female patients than female
controls (30.9% vs 47.4%, P < .001) reported that their sex life
had been good/very good in the past year.
Finally, significantly more female patients than female controls
(26.6% vs 8.3%, P < .001) reported no sexual desire over the
past year. Among men, this difference (3.9% vs 2.1%, P ¼ .321)
did not reach statistical significance, and neither did differences
between patients and controls regarding pleasure and meaning-
fulness of recent sex life.
Significantly more female patients than female controls (32.1%
vs 15.7%, P < .001) had not had any sex life during the past year.
Also, significantly fewer female patients than control women
(25.3% vs 41.7%, P < .001) reported that their sexual needs had
been met to a high/very high extent during the last year.DISCUSSION
The present study found that one-third of men and more than
half of women with RA scored within the range indicative of
sexual dysfunction according to the CSFQ score. Besides, fewer
RA patients than Danes from the general population rated their
current sex life as good or very good. Among both men and
women, the proportion of patients with RA who considered a
good sex life to be important was significantly lower than among
the Danish population, and a similar pattern was detected inquestions concerning the meaningfulness and fulfillment of the
recent sexual life.
The high prevalence of sexual dysfunctions among female
patients with RA was also shown in a recent systematic review
and meta analysis,31 with studies using the Female Sexual
Function Index to measure sexual dysfunction. All domains in
the Female Sexual Function Index were lower in women with RA
than healthy controls and with 79.7% women with RA reporting
sexual dysfunction. Similar to us, Puchner et al32 found increased
sexual dysfunction in all domains among women with RA
(n ¼ 203) compared to healthy controls (n ¼ 169) using the
CSFQ score. No comparisons to males with RA were made, but
a systematic review found an increased prevalence of sexual
dysfunction in men with RA (33e62%) compared to healthy
controls (11e40%).33
A newly published study found sexual dysfunction to be
prevalent in one-third of patients with RA, and gender, age above
50 years, disease activity, mental health, and cohabitation were
among factors associated with sexual dysfunction.34 The present
study found no significant association between sexual dysfunction
and disease activity (measured with the HAQ) or cohabitation.
However, significant associations were present between general
questions about sex life and disease activity, depression, loneliness,
and alcohol consumption. Such questions of a more exploratory
nature were not addressed in the aforementioned studies.
A meta-analysis that investigated RA as a risk factor for sexual
dysfunction among both genders found that both women
(relative risk, 1.73) and men (relative risk, 1.99) with RA had an
increased risk of sexual dysfunction,35 which is in line with our
study. It is essential to take into consideration that although the
CSFQ scores show a high level of possible sexual dysfunction, we
did not measure possible sexual distress.
Several bio-psycho-social factors are known to potentially
impact sexual function, and some of these may be more prom-
inent for patients with RA. Our study revealed that fatigue had a
negative impact on the patients’ sex life and that a high VAS
score of fatigue was significantly associated with the presence of
sexual dysfunction the past year. One out of 4 patients reported
RA-related fatigue, and of these, almost half (47%) claimed that
it affected their sex life negatively. In a study by Hill et al,36 56%
of patients with RA (n ¼ 57; 10 men and 47 women) stated that
they experienced limitations in sexual intercourse, and the main
reasons for this were fatigue or pain. A similar pattern was seen in
a descriptive study among women (n ¼ 100) with a range of
chronic illnesses which found that fatigue was associated with
lower sexual function.37 Fatigue is highly prevalent among pa-
tients with RA.38 Still, despite the indications that it is one of the
most sexually burdensome symptoms of RA, there is a lack of
studies investigating the specific impact of fatigue on RA pa-
tients’ general and sexual well-being.
Our results showed that moderate to severe depression was
present more in female than in male respondents (12.8% vsSex Med 2020;8:615e630
Table 4. Multivariate analysis of possible determinants of sexual ill health
Characteristics
Sexual dysfunction
during last month**
Bad/very bad sex
life during last year
Sex life not at
all/to a low extent
meaningful during
last year
Sexual needs not
at all/to a low extent
accommodated during
last year
Sex life to a
high/some extent
more complicated
because of RA
Ever experienced
sexual problems
due to RA treatment
RA induced
negative body
image
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Sociodemographic data
Gender
Male 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Female 2.5 (1.3e4.8) 0.9 (0.4e2.8) 1.1 (0.4e2.6) 1.1 (0.5e2.4) 1.3 (0.6e2.7) 0.9 (0.5e1.8) 1.5 (0.7e3.3)
Age group
Age < 45 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Age 45e65 3.5 (1.3e9.4) 1.1 (0.3e4.7) 3.8 (0.9e15.4) 3.6 (0.8e17.0) 0.7 (0.3e1.9) 1.0.(0.4e2.7) 0.4 (0.2e0.9)
Age 65þ 10.6 (3.5e32.5) 0.6 (0.1e3.6) 5.7 (1.2e28.2) 3.4 (0.6e18.4) 0.7 (0.2e2.0) 1.1 (0.4e3.1) 0.1 (0.0e0.3)
Cohabitating status
Living alone 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Cohabitating 0.8 (0.3e2.7) 1.37 (0.2e10.5) 0.9 (0.1e5.7) 0.7 (0.1e3.2) 1.3 (0.4e4.6) 0.5 (0.1e2.1) 0.4 (0.1e1.6)
Partner status
Single 1.00 1.00 1.00 1.00 1.00 1.00 1.00
In a relationship 0.6 (0.2e1.8) 1.7 (0.3e11.0) 1.9 (0.3e11.9) 1.2 (0.3e6.0) 0.7 (0.2e2.2) 7.4 (1.7e33.0) 4.3 (1.2e16.4)
Characteristics related to RA
Paraclinical variables
Anti-CCP negative* 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Anti-CCP positive* 2.1 (0.9e4.8) 0.6 (0.2e2.13) 0.8 (0.3e2.3) 2.0 (0.6e6.7) 0.7 (0.3e1.7) 1.1 (0.5e2.7) 0.9 (0.4e2.7)
IgM-RF negative† 1.00 1.00 1.00 1.00 1.00 1.00 1.00
IgM-RF positive† 0.5 (0.2e1.3) 1.01 (0.3e4.0) 1.5 (0.4e5.2) 0.6 (0.2e1.8) 0.9 (0.4e2.5) 0.6 (0.2e1.5) 2.7 (0.9e8.1)
Comorbidity
CCI 0e1 1.00 1.00 1.00 1.00 1.00 1.00 1.00
CCI 2þ 0.7 (0.2e2.7) 1.3 (0.3e6.8) 2.3 (0.4e13.2) 4.4 (1.2e16.2) 4.0 (1.1e15.5) 2.7 (0.7e9.6) 0.9 (0.2e3.8)
Medical treatment related to RA
Methotrexate
Previous 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Current 0.8 (0.4e1.6) 0.8 (0.3e2.3) 0.9 (0.4e2.12) 0.9 (0.4e2.2) 3.3 (1.4e7.7) 1.1 (0.6e2.1) 1.3 (0.6e2.7)
Never 0.4 (0.0e6.6) 2.5 (0.1e72.9) 1.4 (0.1e36.6) 1.00 (.-.)†† 0.9 (0.1e12.5) 0.2 (0.0e3.0) 0.2 (0.1e3.7)
Biologics‡
Previous 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Biologics: present 1.4 (0.5e4.2) 2.1 (0.4e11.8) 1.3 (0.3e5.5) 0.6 (0.2e2.0) 0.4 (0.1e1.4) 0.9 (0.3e2.9) 0.7 (0.2e2.1)
Biologics: never 2.1 (0.8e6.0) 2.6 (0.5e12.7) 1.5 (0.4e5.7) 0.4 (0.1e1.1) 0.9 (0.3e2.8) 0.8 (0.3e2.3) 0.5 (0.2e1.5)
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Table 4. Continued
Characteristics
Sexual dysfunction
during last month**
Bad/very bad sex
life during last year
Sex life not at
all/to a low extent
meaningful during
last year
Sexual needs not
at all/to a low extent
accommodated during
last year
Sex life to a
high/some extent
more complicated
because of RA
Ever experienced
sexual problems
due to RA treatment
RA induced
negative body
image
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Lifestyle factors
BMI categories§
<18.5 0.8 (0.2e3.7) 0.9 (0.1e16.3) 4.3 (0.4e45.6) 0.8 (0.1e10.9) 2.2 (0.3e14.9) 1.5 (0.2e9.7) 3.5 (0.5e27.1)
18.5e24 1.00 1.00 1.00 1.00 1.00 1.00 1.00
25e29 1.1 (0.6e2.2) 1.1 (0.4e3.1) 0.9 (0.4e2.4) 1.9 (0.8e4.4) 1.1 (0.5e2.3) 0.6 (0.3e1.2) 1.0 (0.5e2.1)
30e39 0.9 (0.5e2.1) 1.1 (0.4e3.2) 2.0 (0.8e5.1) 1.8 (0.7e4.7) 1.0 (0.5e2.4) 0.7 (0.3e1.5) 1.7 (0.8e3.7)
40þ 1.9 (0.3e14.3) 2.0 (0.2e22.2) 4.4 (0.3e55.9) 5.7 (0.8e38.0) 0.5 (0.0e6.0) 0.3 (0.0e2.3) 0.5 (0.0e4.0)
Smoking categories
No daily smoking 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Daily smoking 0.6 (0.3e1.3) 0.7 (0.2e2.4) 1.4 (0.5e3.9) 1.3 (0.5e3.3) 1.4 (0.6e3.1) 0.7 (0.3e1.5) 1.6 (0.7e3.6)
Alcohol categories
No weekly alcohol 1.00 1.00 1.00 1.00 1.00 1.00 1.00
<7/<14 units/week 1.1 (0.6e2.1) 1.4 (0.5e3.9) 1.1 (0.5e2.7) 1.5 (0.7e3.4) 2.2 (1.1e4.5) 1.3 (0.6e2.5) 2.0 (0.9e4.1)
>7/>14 units/week 0.9 (0.3e2.7) 0.9 (0.2e4.2) 0.3 (0.1e1.4) 0.6 (0.1e2.8) 2.2 (0.7e6.7) 1.1 (0.4e3.1) 3.4 (1.2e9.9)
Patient-reported outcomes
Physical function categoriesk
HAQ 0e1 1.00 1.00 1.00 1.00 1.00 1.00 1.00
HAQ 1e2 1.6 (0.8e3.3) 0.9 (0.3e2.7) 1.1 (0.4e2.9) 0.8 (0.4e1.9) 0.4 (0.2e0.9) 1.3 (0.6e2.7) 1.3 (0.6e2.7)
HAQ 2e3 2.0 (0.4e8.8) 3.1 (0.5e19.6) 2.9 (0.5e15.9) 2.8 (0.7e11.8) 0.8 (0.2e3.8) 2.0 (0.5e7.6) 0.8 (0.2e3.5)
Depression categories{
BDI  13 1.00 1.00 1.00 1.00 1.00 1.00 1.00
BDI 14e19 2.4 (0.9e6.1) 4.4 (1.5e13.3) 2.9 (0.9e8.7) 2.8 (1.1e7.3) 1.7 (0.6e4.9) 1.0 (0.4e2.5) 2.1 (0.9e5.3)
BDI 20e28 2.4 (0.6e9.7) 3.3 (0.8e13.4) 2.1 (0.5e10.0) 1.0 (0.3e4.1) 1.5 (0.3e6.7) 1.7 (0.5e5.7) 4.5 (1.3e15.3)
BDI  29 1.8 (0.1e26.1) 31.9 (1.9e546.9) 5.6 (0.3e101.8) 2.5 (0.2e29.6) 1.00 (.-.)†† 1.9 (0.2e17.2) 38.3 (2.3e636.4)
Loneliness categories#
UCLA 20e34 1.00 1.00 1.00 1.00 1.00 1.00 1.00
UCLA 35e49 1.8 (0.9e3.3) 2.6 (0.9e7.5) 3.7 (1.5e8.9) 1.4 (0.7e3.1) 0.5 (0.3e1.0) 2.9 (1.5e5.6) 1.8 (0.9e3.6)
UCLA 50e64 1.8 (0.7e5.0) 6.0 (1.6e23.3) 6.1 (1.5e25.1) 1.7 (0.6e5.3) 0.5 (0.1e1.5) 1.5 (0.5e4.3) 0.9 (0.3e2.7)
UCLA 65e80 1.00 (.-.)†† 1.00 (.-.)†† 1.00 (.-.)†† 1.00 (.-.)†† 1.00 (.-.)†† 11.0 (0.4e299.5) 0.3 (0.1e8.7)
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Table 4. Continued
Characteristics
Sexual dysfunction
during last month**
Bad/very bad sex
life during last year
Sex life not at
all/to a low extent
meaningful during
last year
Sexual needs not
at all/to a low extent
accommodated during
last year
Sex life to a
high/some extent
more complicated
because of RA
Ever experienced
sexual problems
due to RA treatment
RA induced
negative body
image
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Pain categories
VAS Pain 0e34 1.00 1.00 1.00 1.00 1.00 1.00 1.00
VAS Pain 35e74 0.7 (0.3e1.4) 0.8 (0.3e2.4) 0.3 (0.1e0.8) 0.6 (0.3e1.5) 0.7 (0.3e1.4) 1.4 (0.7e2.9) 0.9 (0.4e2.1)
VAS Pain 75þ 1.2 (0.2e7.9) 0.6 (0.1e5.3) 0.4 (0.0e4.3) 0.9 (0.1e5.3) 0.7 (0.1e6.0) 2.2 (0.4e11.8) 1.3 (0.3e6.9)
Fatigue categories
VAS Fatigue 0e34 1.00 1.00 1.00 (.-.) 1.00 1.00 1.00 1.00
VAS Fatigue 35e74 1.9 (0.9e4.1) 2.4 (0.7e8.4 4.7 (1.7e12.9) 1.7 (0.7e4.4) 0.4 (0.2e0.9) 0.9 (0.4e2.0) 1.3 (0.6e3.0)
VAS Fatigue 75þ 4.1 (1.4e12.3) 1.3 (0.3e6.3) 2.1 (0.4e10.2) 2.7 (0.7e9.7) 0.6 (0.2e2.1) 1.1 (0.4e3.2) 1.6 (0.5e4.9)
Abbreviations: BDI ¼ Beck Depression Inventory; BMI ¼ body mass index; CCI ¼ Charlson’s Comorbidity Index; CCP ¼ cyclic citrullinated peptide; CI ¼ confidence interval; HAQ ¼ Health Assessment
Questionnaire; IgM-RF ¼ immunoglobulin M rheumatoid factor; MTX ¼methotrexate; OR ¼ odds ratio; RA ¼ rheumatoid arthritis; UCLA ¼ University of California Los Angeles; VAS ¼ Visual Analog Scale.
All ORs are mutually adjusted for all characteristics included in the table. Bold values indicating OR to be significantly different from 1 at a 0.05 significance level.
*Anti-CCP positive/negative, cutoff as defined by local laboratory.
†IgM-RF positive/negative, cutoff as defined by local laboratory.
‡Biologics include anakinra, tocilizumab, abatacept, etanercept, certolizumab, adalimumab, infliximab, golimumab.
§BMI categories: <18.5 underweight; 18.5e24.9 normal weight; 25e29.9 overweight; >30e39.9 severe overweight; BMI >40 extreme overweight.
ǁHAQ categories: 0e1 mild to moderate difficulty; 1e2 moderate to severe disability; 2e3 severe to very severe disability.
{BDI categories: 13 minimal or no depression; 14e19 light depression; 20e28 moderate depression; 29 severe depression.
#UCLA Loneliness categories: 20e34, low; 35e49, moderate; 50e64, moderately high; 65e80, high.
**Sexual dysfunction measured with CSFQ score, cutoff 47 for men and 41 for women.
††Numbers too small to calculate OR and CI.
S
ex
M
ed
20
20
;8
:6
15
e
6
30
S
exualH
ealth
&
D
yfunction
in
Patients
W
ith
R
A
6
25
Table 5. Key questions about sexual health in the rheumatoid arthritis (RA) sample and the general population*
Respondents
Male Female
Patients with
RA, n (%)
General
population,* n (%)
Patients with
RA, n (%)
General
population,* n (%)
How important is it for you to have a good sex
life?
n ¼ 77,
n ¼ 22,870
n ¼ 239
n ¼ 22,892
P† ¼ 0.012 P < .001
Highly important/very important/important 61 (79.2%) 20,644 (90.3%) 129 (54.0%) 17,266 (75.4%)
Not important/not important at all 13 (16.9%) 2,067 (9.0%) 93 (38.9%) 5,323 (23.3%)
Don’t know 3 (3.9%) 158 (0,7%) 17 (7.1%) 343 (1.5%)
During the last year, how would you generally
appraise your sex life?
n ¼ 77,
n ¼ 22,870
n ¼ 237,
n ¼ 22,892
P ¼ .043 P < .001
Very good/good 30 (39.0%) 11,413 (49.9%) 73 (30.9%) 10,844 (47.4%)
Neither good nor bad 30 (39.0%) 5,943 (26.0%) 46 (19.4%) 5,299 (23.1%)
Bad/very bad 9 (11.7%) 3,779 (16.6%) 31 (13.1%) 2,953 (12.9%)
Did not have any sexual life 5 (6.5%) 1,652 (7.2%) 76 (32.1%) 3,600 (15.7%)
Don’t know 3 (3.9%) 79 (0,4%) 11 (4.6%) 196 (0,9%)
During the last year, to what extent did you
experience your sex life as a meaningful and
rewarding part of life?
n ¼ 72,
n ¼ 21,218
n ¼ 161,
n ¼ 19,292
P ¼ .390 P ¼ .063
To a very high/high extent 28 (38.9%) 10,519 (49.6%) 53 (32.9%) 8,676 (45.0%)
To some extent 23 (32.0%) 6,125 (28.9%) 50 (31.0%) 6,023 (31.2%)
To a low extent/not at all 16 (22.2%) 4,317 (20.3%) 41 (25.5%) 4,182 (21.7%)
Don’t know 5 (6.9%) 257 (1.2%) 17 (10.6%) 410 (2.1%)
During the last year, to what extent were your
sexual needs accommodated?
n ¼ 77,
n ¼ 22,870
n ¼ 237,
n ¼ 22,892
P ¼ .321 P < .001
To a very high/high extent 26 (33.8%) 8,791 (38.4%) 60 (25.3%) 9,555 (41.7%)
To some extent 30 (39.0%) 7,881 (34.5%) 55 (23.2%) 6,055 (26.5%)
To a low extent/not at all 15 (19.5%) 5,585 (24.4%) 45 (19.0%) 4,998 (21.8%)
Did not have sexual desires 3 (3.9%) 470 (2.1%) 63 (26.6%) 1,911 (8.3%)
Don’t know 3 (3.9%) 142 (0.6%) 14 (6.0%) 379 (1.7%)
Significant P values emphasized in bold.
*Weighted data from the Project SEXUS cohort (25- to 73-year-old respondents).22
†P values comparing RA sample and general population stratified by gender, bold P values indicate significance at the <0.05 level, P value calculated by c2
test.
626 Bay et al2.6%), generally leaving women in a more vulnerable position.
Imran et al39 reported overall higher rates of depression among
patients with RA (n ¼ 100) than our study; they found that
22.5% had moderate depression, while 18.6% had severe
depression measured with BDI. Although the results from our
study showed a lesser extent of depression in patients with RA,
multivariate analysis revealed an association between both light
and severe depression and the experience of a bad/very bad sex life.
It is well known from other studies that depression and sexual
function are closely linked and that the relationship between
depression and sexual dysfunction can be bidirectional.40 Results
from a previous cross-sectional study investigating depression and
sexual function in patients with RA showed that depression, along
with age and female sex, was predictive of sexual dysfunction. This
was independent of other physical aspects.7The present study also showed an association between
moderate/severe depression and a negative body image induced
by RA, and nearly one-third of the patients (30%; 32% of
females vs 22% of males) stated that RA had negatively altered
their body image. In contrast, just 5.6% of the patients
thought that RA had changed their partner’s appraisal of their
body negatively, but 25.0% responded that they were unaware
of how their partner felt of their body. These results are in
line with 2 other smaller studies. In a study of 82 men and
women, Jorge et al found a significant worse body image
perception as well as lower self-esteem in patients with RA
compared to healthy controls.41 Monaghan et al found that
concerns of appearance and physical functioning were pre-
dictive of depression in men and women with recent-onset or
chronic RA.42Sex Med 2020;8:615e630
Sexual Health & Dyfunction in Patients With RA 627Furthermore, our study found that a moderate to high lone-
liness score was associated with experiencing sexual problems and
not finding one’s current sex life meaningful. Data from the same
cohort have previously shown that the existence of loneliness can
be tabooed, although it is generally burdensome for persons with
RA.43 Studies on sexual dysfunction and loneliness are scarce.
One cross-sectional study investigating the correlation between
sexual dysfunction and loneliness among patients on hemodial-
ysis found no association.44 A study on (healthy) older adults
found that a higher score on the UCLA Loneliness Scale was
associated with less frequent sexual activity and fewer feelings of
intimacy, indicating sexual dysfunction.45
In our sample, 18.4% of the men reported having ever used
medication for treating erectile dysfunction, and 63.6% of the
male patients showed signs of an arousal/excitement dysfunction.
Erectile dysfunction is a well-known complication of several
chronic diseases, especially cardiovascular disease and diabetes.46
Still, only a few studies have previously shown an increased risk
of erectile problems in male patients with RA.47,48 Male sexual
function can be affected by testosterone,49 and this was examined
in a small sample of men with RA, showing decreased testos-
terone levels and increased ED and lack of libido compared to
healthy controls.50 Unfortunately, we were not able to collect
data on the testosterone levels of male participants.
Medical side effects are well-documented reasons for sexual
problems.51-53 In our sample, 30.3% of men and 28.9% of
women had ever experienced a negative impact of RA medication
on their sexual life. Nearly all our patients were presently or
previously treated with MTX, and 29.2% were currently being
treated with biological treatment. A few studies have shown that
MTX for dermatological use may cause loss of libido or erectile
dysfunction,11 but larger scale studies are needed.
The impact of RA treatment on female sexual dysfunction is
scarcely investigated. Although Alia et al54 found no association
between RA treatment and female sexual function, our results
suggest that men and women may equally experience negative
influence on their sex life from the medical treatment. It is
generally difficult to differentiate between the adverse effects of
the disease and its treatment, but based on our findings, clini-
cians should consider adverse sexual events caused by medication
in both men and women. However, further research is needed to
confirm the suggested associations between medical RA treat-
ment and sexual dysfunction.
Female dysfunction in the subdomain of sexual arousal/
excitement could be explained by either drug-related side ef-
fects40 or Sjögren’s disease that may accompany RA, leading to
vaginal dryness.55 Also, reduced lubrication is prevalent after
menopause,56 and this may aggravate existing risk factors of
sexual dysfunction in postmenopausal RA patients. Lubrication
problems have been explicitly investigated in premenopausal
patients with breast cancer.57 Still, to our knowledge, no studies
have as yet shed light on drug-induced vaginal dryness in women
with RA.Sex Med 2020;8:615e630Finally, our study showed that the majority of both male and
female patients (92%; 86% of men vs 94% of women) had not
discussed sexual questions or problems with a health-care pro-
fessional in the last 5 years. A total of 83% (72% of men vs 86%
of women) had not experienced any health-care provider address
sex life issues during the past year. These results are similar to
findings from other studies, including both patients with RA and
patients with other chronic illnesses. For example, Josefsson and
Gard9 found that 75% of Swedish patients with RA had never
discussed sexual questions in the consultation, while 65%
expressed a wish to talk to a health professional about such
topics. Similarly, a Danish study on men and women with heart
diseases showed that even in patients with conditions with a well-
known adverse effect on sexual function, most patients experi-
enced that sexual issues were not addressed in the consultation.16
Surprisingly, half of the participants in our study stated that
they did not want health-care professionals to address sexual
themes occasionally. This is in contrast to the aforementioned
Swedish study,9 where just 14% of the participants did not want
to receive any information about sexuality from health pro-
fessionals, while 27% preferred to discuss sexual issues with their
partner. However, it should be noted that 18% of women and
12% of men in our study answered “Don’t know” to the question
about the need for a clinical dialog about sexual topics, suggesting
a general perception of sexual problems and sexual dysfunction as
a sensitive subject. It is, thus, well known that a “two-way taboo”
may exist, where both patients and professionals avoid the subject,
waiting in vain for the other part of bringing it up.17 This
silencing may leave patients with RA in a vulnerable position,
where refusing a need to discuss sexual problems seems more
natural than to bring the issue up. Such a dynamic is supported by
several other studies,14,58 and it may also be part of the reason why
significantly more RA patients than Danes from the general
population deemed a good sex life unimportant.CONCLUSION AND CLINICAL PERSPECTIVES
Our results confirm and add to existing knowledge of sexual
problems and ill health among both male and female patients
with RA. Sexual adversities may be caused directly by RA-specific
changes (ie, pain, fatigue, or medical side effects), but they may
also result from indirect or confounding factors such as high
body mass index, comorbidity, depression, loneliness, or body
image disturbances. Furthermore, old age and female gender
seem to increase the risk of sexual problems in patients with RA.
Results from our study indicate that having RA can make
patients’ sexual life more complicated, impact their body image
negatively, or raise speculations about future sexual health. One-
third of patients with RA would like to discuss sexual issues
openly with their health-care provider, but the vast majority of
patients have not been invited to such talks. This underscores the
importance of a holistic approach in rheumatological practice,
and doctors and nurses should be aware that a significant
628 Bay et alproportion of their patients have unmet needs for sexual infor-
mation and counseling. Thus, health-care professionals should
actively disrupt the “two-way taboo” to ensure the sexual and
relational health of their patients with RA. Also, issues such as
depression, loneliness, insecurity, and body image disorders
should be considered when RA patients are expressing sexual
difficulties.Strengths and Limitations of the Study
The strengths of the study include its relatively large sample size of
350 patients. In addition, it is a strength that 79men were included,
as most RA studies restrict themselves to investigating female pa-
tients. However, a larger number of male participants would have
strengthened the study and made its conclusions more robust.
The study limitations include a significant risk of selection
bias. Patients were recruited consecutively, as they showed up in
the outpatient department. Thus, patients with deficient disease
activity (who did not feel a need to show up) or very high disease
activity (who did not have the strength to show up) may have
been missed because of nonattendance. The same may be right
for low-resource and poorly adherent patients. Although there
was a relatively high response rate (86.5%), there is a risk of
nonresponse bias because we have no data on the dropouts and
nonresponders. Recall bias and social desirability bias may also be
present, primarily because some of the questionnaires dealt with
delicate questions on private and intimate matters.59
The cross-sectional study design did not allow for a dynamic
lifetime approach.
Furthermore, the lack of a healthy control group to directly
compare with the included patient-reported outcome measures
(BDI; UCLA; CSFQ) impaired conclusions regarding the impact
and causality of various risk factors.
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